Monitoring Rectal Cancer Treatment with MRI-guided Radiotherapy
This observational study is looking at how well a special type of MRI scan, called on-board DWI sequences, can predict treatment response in people with rectal adenocarcinoma (a type of colon cancer). You would receive standard radiotherapy treatment using an MRI-guided system. During your treatment, these special MRI scans would be done every three treatment sessions, taking about 3-4 minutes each time. Researchers want to see if the results from these scans, specifically a measurement called Apparent Diffusion Coefficient (ADC), can tell us early on how well the treatment is working. To join, you need to be over 18, have been diagnosed with rectal adenocarcinoma, and be healthy enough for treatment. The study is currently unclear on its status.
- Study design
- This is an observational study with a planned enrollment of 39 participants. It is not a randomized study.
- What's involved
- You would receive MRI-guided radiotherapy, and on-board DWI sequences would be performed every three treatment sessions, lasting 3-4 minutes each. The primary measurement will be taken at surgery, 5 to 10 weeks after chemoradiation ends.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint is measured at surgery, 5 to 10 weeks after completing chemoradiation.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
At a glance
Conditions
NCT03961776
Where you'd take part
This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Institut Paoli Calmettes
Marseille, Bouches Du Rhone, Francestudy coordinator listed
Recruiting
University of California Los Angeles (UCLA)
Los Angeles, Californiano site contact published
Not yet recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Marguerite TYRAN, MD · PRINCIPAL_INVESTIGATOR · Institut Paoli-Calmettes
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Predictive value of Apparent Diffusion Coefficient measured using MRgRT systemAt surgery (5 to 10 weeks after completion of chemoradiation)
Pathological complete response using AJCC criteria